Sana Biotechnology, Inc. (SANA)
| Market Cap | 919.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -244.17M |
| Shares Out | 274.37M |
| EPS (ttm) | -0.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,346,742 |
| Open | 3.260 |
| Previous Close | 3.260 |
| Day's Range | 3.250 - 3.380 |
| 52-Week Range | 1.600 - 6.550 |
| Beta | 2.07 |
| Analysts | Strong Buy |
| Price Target | 7.80 (+132.84%) |
| Earnings Date | May 7, 2026 |
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therap... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for SANA stock is "Strong Buy." The 12-month stock price target is $7.8, which is an increase of 132.84% from the latest price.
News
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract ...
Sana Biotechnology Transcript: The Citizens Life Sciences Conference 2026
The conference highlighted advances in hypoimmune cell therapies for Type 1 diabetes, including a year-long successful human case and scalable manufacturing progress. In vivo CAR T cell programs are set for clinical trials this year, with human data expected by year-end.
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evad...
Sana Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference
Key programs target immune-evasive cell therapies for type 1 diabetes and in vivo CAR T-cells for blood cancers, with pivotal clinical and regulatory milestones expected within 12–24 months. Manufacturing scalability, safety, and commercial strategy are central to future success.
Sana Biotechnology to Present at March 2026 Investor Conferences
SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant progress was reported in developing gene-edited cell therapies for type 1 diabetes and in vivo CAR T platforms, with first-in-human data showing immune evasion and ongoing function. IND filing and phase I trials are planned for this year, and manufacturing scale-up and partnerships are key future priorities.
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology
Sana Biotechnology Transcript: Evercore ISI 8th Annual HealthCONx Conference
The discussion highlighted progress toward a functional cure for type 1 diabetes using gene-modified, immune-evasive islets, with IND submission targeted for next year and clinical trials expected in 2026. Manufacturing scale-up and regulatory alignment are underway, and the in vivo CAR-T platform shows promising preclinical results.
Sana Biotechnology Transcript: Citi Annual Global Healthcare Conference 2025
The company is advancing two main programs: a gene-edited, immune-evasive cell therapy for type 1 diabetes targeting IND and phase I trial next year, and an in vivo CAR T platform for blood cancers and autoimmune diseases. Manufacturing scale and safety are key challenges, with partnerships considered for long-term commercialization and platform diversification.
Sana Biotechnology to Present at December 2025 Investor Conferences
SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology Transcript: TD Cowen Immunology and Inflammation Summit
SC451, a gene-modified islet therapy for type 1 diabetes, is advancing toward IND and clinical trials in 2026, with strong proof of concept and a focus on scalable manufacturing. The in vivo CAR T platform is also progressing, with capital allocation ensuring diabetes remains the top priority.
Sana Biotech Stock — The Next '100-Bagger'?
Sana Biotechnology, Inc. (NASDAQ:SANA) shares soared on Wednesday after outspoken stock promoter Eric Jackson named it as his latest potential “100-bagger.”
Sana Biotechnology Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Key advances were presented in immune-evasive cell therapies for type 1 diabetes, with six-month clinical data showing insulin production without immunosuppression. Ongoing CAR-T programs for autoimmune and blood cancers are progressing, with new IND filings planned for 2025 and 2026.
Sana Biotechnology Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Significant progress has been made toward a curative, gene-modified cell therapy for type 1 diabetes, with a pivotal patient case published and IND filing for SC-451 planned next year. The company maintains a unique competitive position, prioritizes capital for diabetes, and advances a promising fusogene platform amid industry-wide challenges in scaling and reimbursement.
Sana Biotechnology Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
The discussion highlighted advances in gene-edited cell therapies for type 1 diabetes, with first-in-human data showing durable insulin production without immunosuppression. Manufacturing and regulatory milestones are progressing, with an IND targeted for 2026. In vivo and allogeneic CAR T programs show promise but require partnerships or funding to advance.
Sana Biotechnology Transcript: Citi's Biopharma Back to School Conference
The discussion highlighted progress in cell therapy platforms, with SC-451 for type 1 diabetes as the lead asset. IND filing is targeted for next year, with rapid trial initiation expected. Manufacturing scale-up and strategic partnerships are key to advancing both diabetes and CAR T programs.
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass.
Sana Biotechnology to Present at September 2025 Investor Conferences
SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca...
Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares
SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it h...
Sana Biotechnology Announces Pricing of Public Offering
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it h...
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it h...
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (a...
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
Data Demonstrate that Sana's Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes
Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression